fenofibrate has been researched along with Cholestasis in 9 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
Cholestasis: Impairment of bile flow due to obstruction in small bile ducts (INTRAHEPATIC CHOLESTASIS) or obstruction in large bile ducts (EXTRAHEPATIC CHOLESTASIS).
| Excerpt | Relevance | Reference |
|---|---|---|
| " We report a woman on long-term therapy with raloxifen who developed acute cholestasis shortly after starting fenofibrate." | 7.73 | Prolonged cholestasis after raloxifene and fenofibrate interaction: A case report. ( Andrade, RJ; García-Muñoz, B; González, FJ; Lucena, MI; Pachkoria, K; Vicioso, L, 2006) |
| "Adult patients with primary biliary cholangitis (PBC, n = 32) and primary sclerosing cholangitis (PSC, n = 23), who experienced an incomplete response while receiving ursodiol monotherapy (13-15 mg/kg/day), defined as serum alkaline phosphatase (ALP) ≥ 1." | 5.62 | Adjunct Fenofibrate Up-regulates Bile Acid Glucuronidation and Improves Treatment Response For Patients With Cholestasis. ( Assis, DN; Barbier, O; Boyer, JL; Gallucci, GM; Ghonem, NS; Hemme, C; Trottier, J, 2021) |
| "Fenofibrate was reported to be beneficial for cholestasis in combination with ursodeoxycholic acid." | 3.96 | Therapeutic action against chronic cholestatic liver injury by low-dose fenofibrate involves anti-chemotaxis via JNK-AP1-CCL2/CXCL2 signaling. ( Dai, M; Liu, A; Luo, Y; Xu, G; Xu, L; Yang, J; Zhang, H, 2020) |
| " This study aims to evaluate the effect of short-term administration of fenofibrate, a PPARalpha agonist, on proinflammatory cytokines, apoptosis, and hepatocellular damage in cholestasis." | 3.74 | Peroxisome proliferators-activated alpha agonist treatment ameliorates hepatic damage in rats with obstructive jaundice: an experimental study. ( Akin, O; Alper, M; Cindoruk, M; Erdem, O; Karakan, T; Kerem, M; Salman, B; Unal, S, 2007) |
| " We report a woman on long-term therapy with raloxifen who developed acute cholestasis shortly after starting fenofibrate." | 3.73 | Prolonged cholestasis after raloxifene and fenofibrate interaction: A case report. ( Andrade, RJ; García-Muñoz, B; González, FJ; Lucena, MI; Pachkoria, K; Vicioso, L, 2006) |
| "Adult patients with primary biliary cholangitis (PBC, n = 32) and primary sclerosing cholangitis (PSC, n = 23), who experienced an incomplete response while receiving ursodiol monotherapy (13-15 mg/kg/day), defined as serum alkaline phosphatase (ALP) ≥ 1." | 1.62 | Adjunct Fenofibrate Up-regulates Bile Acid Glucuronidation and Improves Treatment Response For Patients With Cholestasis. ( Assis, DN; Barbier, O; Boyer, JL; Gallucci, GM; Ghonem, NS; Hemme, C; Trottier, J, 2021) |
| "Then fenofibrate 25 mg/kg was orally administrated to mice twice/day for 14 days." | 1.62 | Fenofibrate reverses liver fibrosis in cholestatic mice induced by alpha-naphthylisothiocyanate. ( Dai, M; Li, S; Liu, A; Lu, Z; Luo, J; Luo, Y; Qiu, J; Yang, J; Zheng, X, 2021) |
| "Fenofibrate treatment further stimulates biliary phosphatidylcholine secretion in rat hepatocytes, thereby providing a functional correlate." | 1.40 | Peroxisome proliferator-activated receptor α activates human multidrug resistance transporter 3/ATP-binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion. ( Ananthanarayanan, M; Boyer, JL; Ghonem, NS; Soroka, CJ, 2014) |
| "Fenofibrate was discontinued immediately." | 1.32 | Fenofibrate-induced acute cholestatic hepatitis. ( Chang, FY; Chen, TS; Ho, CY; Kuo, TH; Lee, SD; Tsay, SH, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 4 (44.44) | 2.80 |
| Authors | Studies |
|---|---|
| Gallucci, GM | 1 |
| Trottier, J | 2 |
| Hemme, C | 1 |
| Assis, DN | 1 |
| Boyer, JL | 2 |
| Barbier, O | 2 |
| Ghonem, NS | 2 |
| Chen, Y | 3 |
| Yang, S | 3 |
| Liu, L | 3 |
| Yang, X | 3 |
| Duan, Y | 3 |
| Zhang, S | 3 |
| Han, J | 3 |
| Dai, M | 2 |
| Yang, J | 2 |
| Luo, Y | 2 |
| Xu, L | 1 |
| Zhang, H | 1 |
| Xu, G | 1 |
| Liu, A | 2 |
| Lu, Z | 1 |
| Li, S | 1 |
| Luo, J | 1 |
| Zheng, X | 1 |
| Qiu, J | 1 |
| Perreault, M | 1 |
| Rudkowska, I | 1 |
| Levy, C | 1 |
| Dallaire-Theroux, A | 1 |
| Verreault, M | 1 |
| Caron, P | 1 |
| Staels, B | 1 |
| Vohl, MC | 1 |
| Straka, RJ | 1 |
| Ananthanarayanan, M | 1 |
| Soroka, CJ | 1 |
| Ho, CY | 1 |
| Kuo, TH | 1 |
| Chen, TS | 1 |
| Tsay, SH | 1 |
| Chang, FY | 1 |
| Lee, SD | 1 |
| Lucena, MI | 1 |
| Andrade, RJ | 1 |
| Vicioso, L | 1 |
| González, FJ | 1 |
| Pachkoria, K | 1 |
| García-Muñoz, B | 1 |
| Cindoruk, M | 1 |
| Kerem, M | 1 |
| Karakan, T | 1 |
| Salman, B | 1 |
| Akin, O | 1 |
| Alper, M | 1 |
| Erdem, O | 1 |
| Unal, S | 1 |
1 trial available for fenofibrate and Cholestasis
| Article | Year |
|---|---|
Profiling serum bile acid glucuronides in humans: gender divergences, genetic determinants, and response to fenofibrate.
Topics: Bile Acids and Salts; Cholestasis; Female; Fenofibrate; Gene Expression Regulation; Glucuronides; Gl | 2013 |
8 other studies available for fenofibrate and Cholestasis
| Article | Year |
|---|---|
Adjunct Fenofibrate Up-regulates Bile Acid Glucuronidation and Improves Treatment Response For Patients With Cholestasis.
Topics: Adult; Bile Acids and Salts; Cholangitis, Sclerosing; Cholestasis; Drug Therapy, Combination; Female | 2021 |
A novel therapy for hepatic cholestasis treatment-the combination of rosiglitazone and fenofibrate.
Topics: Animals; Cholestasis; Fenofibrate; Liver; Mice; Mice, Inbred C57BL; Necrosis; Rosiglitazone; Ursodeo | 2023 |
A novel therapy for hepatic cholestasis treatment-the combination of rosiglitazone and fenofibrate.
Topics: Animals; Cholestasis; Fenofibrate; Liver; Mice; Mice, Inbred C57BL; Necrosis; Rosiglitazone; Ursodeo | 2023 |
A novel therapy for hepatic cholestasis treatment-the combination of rosiglitazone and fenofibrate.
Topics: Animals; Cholestasis; Fenofibrate; Liver; Mice; Mice, Inbred C57BL; Necrosis; Rosiglitazone; Ursodeo | 2023 |
A novel therapy for hepatic cholestasis treatment-the combination of rosiglitazone and fenofibrate.
Topics: Animals; Cholestasis; Fenofibrate; Liver; Mice; Mice, Inbred C57BL; Necrosis; Rosiglitazone; Ursodeo | 2023 |
A novel therapy for hepatic cholestasis treatment-the combination of rosiglitazone and fenofibrate.
Topics: Animals; Cholestasis; Fenofibrate; Liver; Mice; Mice, Inbred C57BL; Necrosis; Rosiglitazone; Ursodeo | 2023 |
A novel therapy for hepatic cholestasis treatment-the combination of rosiglitazone and fenofibrate.
Topics: Animals; Cholestasis; Fenofibrate; Liver; Mice; Mice, Inbred C57BL; Necrosis; Rosiglitazone; Ursodeo | 2023 |
A novel therapy for hepatic cholestasis treatment-the combination of rosiglitazone and fenofibrate.
Topics: Animals; Cholestasis; Fenofibrate; Liver; Mice; Mice, Inbred C57BL; Necrosis; Rosiglitazone; Ursodeo | 2023 |
A novel therapy for hepatic cholestasis treatment-the combination of rosiglitazone and fenofibrate.
Topics: Animals; Cholestasis; Fenofibrate; Liver; Mice; Mice, Inbred C57BL; Necrosis; Rosiglitazone; Ursodeo | 2023 |
A novel therapy for hepatic cholestasis treatment-the combination of rosiglitazone and fenofibrate.
Topics: Animals; Cholestasis; Fenofibrate; Liver; Mice; Mice, Inbred C57BL; Necrosis; Rosiglitazone; Ursodeo | 2023 |
Therapeutic action against chronic cholestatic liver injury by low-dose fenofibrate involves anti-chemotaxis via JNK-AP1-CCL2/CXCL2 signaling.
Topics: 1-Naphthylisothiocyanate; Animals; Chemokine CCL2; Chemokine CXCL2; Chemotaxis; Cholestasis; End Sta | 2020 |
Fenofibrate reverses liver fibrosis in cholestatic mice induced by alpha-naphthylisothiocyanate.
Topics: 1-Naphthylisothiocyanate; Actins; Animals; Apoptosis Regulatory Proteins; Chemical and Drug Induced | 2021 |
Peroxisome proliferator-activated receptor α activates human multidrug resistance transporter 3/ATP-binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; Bile Canaliculi; Biliary Tract; Cholestasis; | 2014 |
Fenofibrate-induced acute cholestatic hepatitis.
Topics: Acute Disease; Chemical and Drug Induced Liver Injury; Cholestasis; Fenofibrate; Humans; Hypolipidem | 2004 |
Prolonged cholestasis after raloxifene and fenofibrate interaction: A case report.
Topics: Biopsy; Cholestasis; Female; Fenofibrate; Humans; Hypolipidemic Agents; Liver; Middle Aged; Raloxife | 2006 |
Peroxisome proliferators-activated alpha agonist treatment ameliorates hepatic damage in rats with obstructive jaundice: an experimental study.
Topics: Animals; Apoptosis; Bile Ducts; Bilirubin; Cholestasis; Cytokines; Fenofibrate; Hepatocytes; Inflamm | 2007 |